Subscribe
shutterstock_1169341219
Grand Warszawski / Shutterstock.com
25 February 2019Americas

Roche to make $4.3bn gene therapy acquisition

Switzerland-based  Roche will buy gene therapy company  Spark Therapeutics in a $4.3 billion deal.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Catalent to buy $1.2bn gene therapy company
17 April 2019   Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.
Americas
Roche buys fibrotic diseases biotech in $1.4bn deal
19 November 2019   Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.
Americas
Astellas doubles down on gene therapy with $3bn Audentes deal
5 December 2019   Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Catalent to buy $1.2bn gene therapy company
17 April 2019   Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.
Americas
Roche buys fibrotic diseases biotech in $1.4bn deal
19 November 2019   Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.
Americas
Astellas doubles down on gene therapy with $3bn Audentes deal
5 December 2019   Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.

More on this story

Americas
Catalent to buy $1.2bn gene therapy company
17 April 2019   Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.
Americas
Roche buys fibrotic diseases biotech in $1.4bn deal
19 November 2019   Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.
Americas
Astellas doubles down on gene therapy with $3bn Audentes deal
5 December 2019   Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York